Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Dr. Paul  Alloway J.D., Ph.D.

President & Chief Operating Officer

Mr. Charles  Michaud Jr., CPA

Име	Пазарна капитализация
Affimed N.V.	0M
Halozyme Therapeutics, Inc.	0M
Walgreens Boots Alliance Inc	0M
Nektar Therapeutics	0M
Transgene SA	0M
Camurus AB (publ)	0M
Relief Therapeutics Holding AG	0M
Blueprint Medicines Corporation	0M
Pa Shun International Holdings Limited	0M
Invitae Corporation	0M

Homology Medicines, Inc.

Homology Medicines, Inc. Списък на конкурентите

Основни конкуренти